Loading clinical trials...
Loading clinical trials...
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus Obtained Via a Non-invasive Screening Protocol
Nonalcoholic fatty liver disease (NAFLD) is a condition characterized by intrahepatic fat accumulation. It is closely related to insulin resistance. To date, it remains unclear whether NAFLD is common in patients with type 1 diabetes or if NAFLD translates into an increased health burden in this population. Screening for NAFLD is challenging due to the limitations of non-invasive diagnostic tools. Liver biopsy remains the gold standard but is not suited for routine screening or clinical studies. Therefore, there is a great demand for accurate non-invasive screening tools that can not only diagnose but also stage NAFLD. This study aims to generate a large cohort of thoroughly characterized type 1 diabetes patients screened for NAFLD using multiple non-invasive tools including MRI, ultrasound, controlled attenuation parameter, and score panels. We aim to generate a biobank to promote a research collaboration network in the field of non-invasive diagnosis of NAFLD. A secondary endpoint is to investigate the potential correlation between the presence of NAFLD and the occurrence of micro-or macrovascular complications in patients with diabetes.
This study aims to characterize and follow a thoroughly characterized cohort of adult type 1 diabetes patients free from secondary liver disease due to excessive alcohol usage, viral hepatitis, alfa-1 antitrypsin deficiency, Wilson's disease or steatogenic or hepatotoxic drug use. The investigators will screen for NAFLD and fibrosis using multiple non-invasive techniques including * ultrasound * controlled attenuation parameter * fatty liver index * human steatosis index * transient elastography * FIB-4 * NAFLD fibrosis score * NASH algorithm based on multiple parameters Subjects will be screened for microvascular and microvascular complications with: * ECG * microfilament examination * 24hour urine collection for microalbuminuria * serum kidney test (creatinine, eGFR) * fundoscopy * peripheral arterial pulsation palpation The investigators will subsequently thoroughly characterize various metabolic and anthropometric parameters and document any microvascular or macrovascular complications. The patients will be annually rescreened for both NAFLD-related as cardiovascular variables. Therefore this study will assess the correlation between NAFLD, cardiovascular risk, and type 1 diabetes in a prospective manner.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Antwerp University Hospital
Edegem, Antwerp, Belgium
Start Date
September 17, 2018
Primary Completion Date
July 30, 2023
Completion Date
July 30, 2025
Last Updated
March 4, 2022
700
ESTIMATED participants
ultrasound
DIAGNOSTIC_TEST
elastography
DIAGNOSTIC_TEST
controlled attenuation parameter (CAP)
DIAGNOSTIC_TEST
FLI
DIAGNOSTIC_TEST
FIB-4
DIAGNOSTIC_TEST
NFS
DIAGNOSTIC_TEST
Lead Sponsor
University Hospital, Antwerp
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06909773